MX2023002792A - Preparacion farmaceutica. - Google Patents

Preparacion farmaceutica.

Info

Publication number
MX2023002792A
MX2023002792A MX2023002792A MX2023002792A MX2023002792A MX 2023002792 A MX2023002792 A MX 2023002792A MX 2023002792 A MX2023002792 A MX 2023002792A MX 2023002792 A MX2023002792 A MX 2023002792A MX 2023002792 A MX2023002792 A MX 2023002792A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
methoxy
well
quinolin
imidazo
Prior art date
Application number
MX2023002792A
Other languages
English (en)
Inventor
Axel Becker
Markus Riehl
Alessandra Ambruosi
Riccardo Mannini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2023002792A publication Critical patent/MX2023002792A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una preparación farmacéutica sólida de 8-(1,3-dimetil-1H-pirazol-4-il)-1-(Sa)-(3-f luoro-5-metoxi-piridin-4-il)-7-metoxi-3-metil-1,3-dihidro-imidazo [4,5-c]quinolin-2-ona, así como un método para elaborarlo, así como sus usos médicos.
MX2023002792A 2020-09-18 2021-09-15 Preparacion farmaceutica. MX2023002792A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20196904 2020-09-18
PCT/EP2021/075337 WO2022058351A1 (en) 2020-09-18 2021-09-15 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
MX2023002792A true MX2023002792A (es) 2023-03-16

Family

ID=72561655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002792A MX2023002792A (es) 2020-09-18 2021-09-15 Preparacion farmaceutica.

Country Status (13)

Country Link
US (1) US20230330027A1 (es)
EP (1) EP4213803A1 (es)
JP (1) JP2023542496A (es)
KR (1) KR20230069147A (es)
CN (1) CN116456969A (es)
AR (1) AR123539A1 (es)
AU (1) AU2021346097A1 (es)
BR (1) BR112023002078A2 (es)
CA (1) CA3190226A1 (es)
IL (1) IL301412A (es)
MX (1) MX2023002792A (es)
TW (1) TW202227073A (es)
WO (1) WO2022058351A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10531049B2 (en) 2015-03-31 2020-01-07 Nec Corporation Methods and systems for scheduling of sensing platform nodes
KR102652052B1 (ko) 2015-04-02 2024-03-27 메르크 파텐트 게엠베하 이미다졸로닐 퀴놀린 및 atm 키나아제 저해제로서의 이의 용도
CN111867589A (zh) * 2018-03-14 2020-10-30 默克专利股份有限公司 在对象中治疗肿瘤的化合物及其用途
US20220144828A1 (en) * 2019-03-27 2022-05-12 Merck Patent Gmbh Imidazolonylquinoline compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
AU2021346097A1 (en) 2023-03-09
AR123539A1 (es) 2022-12-14
TW202227073A (zh) 2022-07-16
BR112023002078A2 (pt) 2023-03-28
CN116456969A (zh) 2023-07-18
EP4213803A1 (en) 2023-07-26
JP2023542496A (ja) 2023-10-10
CA3190226A1 (en) 2022-03-24
KR20230069147A (ko) 2023-05-18
IL301412A (en) 2023-05-01
US20230330027A1 (en) 2023-10-19
WO2022058351A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
MX2023003778A (es) Compuesto antitumoral, metodo de preparacion y uso del mismo.
EP4365179A3 (en) Novel rapamycin derivatives
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
MA33670B1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
EP4397665A3 (en) Diaryl macrocycle polymorph
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
NZ741291A (en) Stabilizing camptothecin pharmaceutical compositions
WO2013052550A3 (en) Novel imidazole quinoline-based immune system modulators
WO2018038988A3 (en) Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them
NZ602578A (en) Polymorphic forms st-246 and methods of preparation
NZ754944A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
WO2021009676A8 (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists
PH12018500796A1 (en) Cyclic ether derivatives of pyrazolo[1,5-a] pyrimidine-3-carboxamide
NZ719983A (en) Methods of preparing ophthalmic formulations and uses of same
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX2023002792A (es) Preparacion farmaceutica.
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2022006934A (es) Inhibidor de aldosterona sintasa.
FR3102178B1 (fr) Polyamides gélifiants biosourcés
MX2009004777A (es) Derivados de 18,21-didsesoximacbecina para el tratamiento de cancer.
MX2024004955A (es) Liposomas de acido urico.
WO2021072325A8 (en) Compositions of ajulemic acid and uses thereof
CR20240216A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno